scholarly journals 1339: RENAL FUNCTION ESTIMATION USING SERUM CREATININE AND CYSTATIN C IN CRITICALLY ILL PEDIATRIC PATIENTS

2021 ◽  
Vol 50 (1) ◽  
pp. 671-671
Author(s):  
Gideon Stitt ◽  
Julie Fitzgerald ◽  
Marissa Leff ◽  
Kevin Downes
Keyword(s):  
Renal Function ◽  
Serum Creatinine ◽  
Critically Ill ◽  
Cystatin C ◽  
Pediatric Patients ◽  
Function Estimation

scholarly journals Serum Cystatin C as a Marker of Renal Function in Critically Ill Patients With Normal Serum Creatinine

2014 ◽  
Vol 6 (2) ◽  
Author(s):  
Mohammad Mahdi Sagheb ◽  
Soha Namazi ◽  
Bita Geramizadeh ◽  
Amin Karimzadeh ◽  
Mohammad Bagher Oghazian ◽  
...  
Keyword(s):  
Renal Function ◽  
Serum Creatinine ◽  
Critically Ill ◽  
Cystatin C ◽  
Critically Ill Patients ◽  
Normal Serum ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Normal Serum Creatinine

scholarly journals New Biomarkers for the Quick Detection of Acute Kidney Injury

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Abdulmuttalip Simsek ◽  
Volkan Tugcu ◽  
Ali Ihsan Tasci
Keyword(s):  
Acute Kidney Injury ◽  
Serum Creatinine ◽  
Critically Ill ◽  
Cystatin C ◽  
Critically Ill Patients ◽  
Clinical Training ◽  
Kidney Injury ◽  
Urinary Proteins ◽  
New Biomarkers ◽  
Urine And Serum

Acute kidney injury (AKI) is a common and strong problem in the diagnosis of which based on measurement of BUN and serum creatinine. These traditional methods are not sensitive and specific for the diagnosis of AKI. AKI is associated with increased morbidity and mortality in critically ill patients and a quick detection is impossible with BUN and serum creatinine. A number of serum and urinary proteins have been identified that may messenger AKI prior to a rise in BUN and serum creatinine. New biomarkers of AKI, including NGAL, KIM-1, cystatin-C, IL-18, and L-FABP, are more favourable tests than creatinine which have been identified and studied in several experimental and clinical training. This paper will discuss some of these new biomarkers and their potential as useful signs of AKI. We searched the literature using PubMed and MEDLINE with acute kidney injury, urine, and serum new biomarkers and the articles were selected only from publication types in English.

scholarly journals Measurement of renal function in kidney donors using serum cystatin C and β2-microglobulin

2003 ◽  
Vol 40 (6) ◽  
pp. 656-658 ◽  
Author(s):  
George T John ◽  
Jude Joseph Fleming ◽  
Girish S Talaulikar ◽  
R Selvakumar ◽  
Paaulose P Thomas ◽  
...  
Keyword(s):  
Renal Function ◽  
Serum Creatinine ◽  
Cystatin C ◽  
Critical Value ◽  
Critical Values ◽  
Published Data ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Kidney Donors ◽  
Reduced Renal Function

Background: The usefulness of serum cystatin C and serum β2-microglobulin (B2M) as markers of glomerular filtration rate (GFR) were compared in kidney donors before and after nephrectomy. Methods: Blood samples were taken from 28 donors (15 women and 13 men) for serum creatinine, urea, cystatin C and B2M estimation a median of 7 days before and 10 days after nephrectomy. Results: Estimated GFR decreased from a median of 86.2 mL/min/1.73 m2 to 60.3 mL/min/1.73 m2, a median decrease of 28.6%. Serum creatinine increased by 40% and urea by 30.4%; serum cystatin C increased by 31.2% and serum B2M increased by 65.6%. Using published data on biological variation, critical values were calculated. An increase in serum creatinine above 18 µmol/L detected the decline in renal function in 26/28 (92.9%) subjects. Increases in serum B2M greater than a critical value of 0.94 mg/L detected 24/28 (85.7%) of these subjects, but the critical value of 0.59 mg/L for cystatin C detected only 8/28 (28.6%). Conclusion: Using critical values, serial measurement of serum creatinine was better than serum B2M in detecting reduced renal function. Because of its large intraindividual variation, serial serum cystatin C estimation was very poor in detecting reduced renal function.

scholarly journals Serum cystatin C in mouse models: a reliable and precise marker for renal function and superior to serum creatinine

2008 ◽  
Vol 24 (4) ◽  
pp. 1157-1161 ◽  
Author(s):  
S. Song ◽  
M. Meyer ◽  
T. R. Turk ◽  
B. Wilde ◽  
T. Feldkamp ◽  
...  
Keyword(s):  
Renal Function ◽  
Serum Creatinine ◽  
Mouse Models ◽  
Cystatin C ◽  
Serum Cystatin C ◽  
Serum Cystatin

scholarly journals Cystatin C- an early marker indicative of renal dysfunction in critically ill children: a prospective cohort study

2019 ◽  
Vol 6 (5) ◽  
pp. 1981
Author(s):  
Hawwa M.S. Siddiqua ◽  
Mathew John ◽  
V. C. Manoj ◽  
Rati Santhakumar
Keyword(s):  
Acute Kidney Injury ◽  
Cohort Study ◽  
Serum Creatinine ◽  
Renal Dysfunction ◽  
Critically Ill ◽  
Cystatin C ◽  
Prospective Cohort ◽  
Kidney Injury ◽  
Critically Ill Children ◽  
Serum And Urine

Background: Acute kidney injury (AKI) is a sudden onset of kidney failure or kidney damage that happens within a few hours or a few days and can also affect other organs such as brain, heart and the lungs. Hence early diagnosis and intervention is needed to improve the outcome of the children. In these studies this objective was to determine if cystatin C is an early marker indicative of renal dysfunction in critically ill children and to determine if Cystatin C can detect Acute kidney injury earlier than serum creatinine.Methods: This prospective cohort study was undertaken in PICU at Jubilee Mission Medical College from December 2016- May 2018. Blood samples were collected from 34 critically ill children for serum creatinine estimation at 0,24 and 48 hours of admission and serum and urine were collected for cystatin C estimation at admission. Children were categorized into AKI and NON-AKI based on pRIFLE criteria. Comparison of cystatin C values with serum creatinine was performed and Statistical analysis was done using IBM SPSS version 20.Results: A total of 34 critically ill children were enrolled in this study, out of which 12 children progressed to AKI during the course of illness according to modified Pediatric Risk, Injury, Failure, Loss, End Stage Renal Disease (pRIFLE) criteria. We found a strong positive correlation between cystatin C at 0 hours and serum creatinine at 48 hours among AKI groups.Conclusions: Serum and Urine cystatin C are early markers to diagnose AKI in critically ill children. Serum cystatin C is more sensitive than urine cystatin C for the diagnosis of AKI.

scholarly journals Cystatin C is a Better Marker of Renal Dysfunction in Hypertensive Pregnancies

2016 ◽  
Vol 20 (1) ◽  
pp. 21-27 ◽  
Author(s):  
Rajeev Ranjan ◽  
Anjana Singh
Keyword(s):  
Renal Function ◽  
Uric Acid ◽  
Serum Creatinine ◽  
Renal Dysfunction ◽  
Cystatin C ◽  
Normal Pregnancy ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Function Tests ◽  
Renal Function Tests

ABSTRACT Background Glomerular endotheliosis is an essential component in the pathophysiology of gestational hypertension (GH) and preeclampsia (PE) which results in renal dysfunction. This is not always detected by routine renal function tests, such as serum creatinine, urea, and uric acid. Cystatin C, an endogenous cysteine protease inhibitor, is completely absorbed by renal tubules and has been shown to be an ideal marker of glomerular filtration rate (GFR), which needs to be evaluated in assessing renal dysfunction occurring in GH and PE. Aims The present study is designed to evaluate serum cystatin C levels in normal pregnancy, GH, and PE and compare its efficacy with traditional renal function tests. Materials and methods In this prospective cross-sectional study, 75 subjects enrolled, comprised of 25 subjects each of normal pregnancy, GH, and PE. Serum cystatin C, blood urea, serum creatinine, serum uric acid, and urinary protein/creatinine ratio were estimated in all subjects prior to delivery. Results All renal parameters including cystatin C were significantly raised in GH and PE compared with control group. However, only serum cystatin C level (and no other renal parameters) was significantly higher in PE group compared with GH group. Area under the curve for cystatin C was maximum (0.917) compared with other parameters. Cystatin C had a higher sensitivity and specificity than other conventional markers. Conclusion Serum cystatin C is a better marker of renal dysfunction in hypertensive pregnancies. How to cite this article Singh A, Gupta M, Ranjan R, Saini V, Gupta SK. Cystatin C is a Better Marker of Renal Dysfunction in Hypertensive Pregnancies. Indian J Med Biochem 2016; 20(1):21-27.

Factors contributing to discrepant estimated glomerular filtration values measured by creatinine and cystatin C in patients with rheumatoid arthritis

2020 ◽  
Author(s):  
Mitsuhiro Kawano ◽  
Akikatsu Nakashima ◽  
Shigeto Horita ◽  
Takahiro Matsunaga ◽  
Ryo Inoue ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Diabetes Mellitus ◽  
Renal Function ◽  
Serum Creatinine ◽  
Cystatin C ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Stage 4 ◽  
Group A ◽  
Group B

Abstract Background This study aimed to clarify the factors underlying the discrepancy that has been noted between estimated glomerular filtration ratio (eGFR) measured using serum creatinine (Cr) and eGFR using serum cystatin C (CysC) in patients with rheumatoid arthritis (RA) and to identify those patients whose renal function should be evaluated using CysC.Methods We retrospectively evaluated clinical features, disease activity, radiological grading, and co-morbidities (diabetes mellitus, hypertension, dyslipidemia) in 238 RA patients. eGFR using serum creatinine (eGFR-Cr) and eGFR using serum cystatin C (eGFR-CysC) were calculated using the new Japanese coefficient-modified Modification of Diet in Renal Disease study equation. To clarify the cause(s) of differences of 20% or more between the two eGFRs, we divided our RA patients into Group A (eGFR-Cr/eGFR-CysC ≥ 1.2), with eGFR-Cr more than 20% higher than eGFR-CysC, and Group B (eGFR-Cr/eGFR-CysC < 1.2), and compared various clinical parameters between them.Results Forty-five patients (18.9%) were assigned to Group A, and 193 (81.1%) to Group B. Group A were older (73.8 ± 12.5 vs 63.2 ± 13.6 years), and had a longer disease duration (17.7 ± 14.0 vs 10.4 ± 9.5 years), lower body mass index (BMI) (20.0 ± 2.9 vs 22.4 ± 3.6 kg/m2), higher frequencies of hypertension and diabetes mellitus (55.6% vs 30.1% and 35.6% vs 11.0%, respectively), higher DAS28-ESR (3.1 ± 1.3 vs 2.6 ± 1.0), lower hemoglobin (Hb) (11.8 ± 1.8 vs 12.8 ± 1.4 g/dl), lower creatine kinase (CK) (63.9 ± 36.0 vs 92 ± 79 IU/L), higher frequency of Steinbrocker stage 4 (46.7% vs. 15.3%), and a lower frequency of nonsteroidal anti-inflammatory drugs (NSAID) use (13.3% vs 30.6%), all significantly (p < 0.01) by a univariate analysis. BMI (Odds Ratio [OR] 0.820, 95% confidence interval [CI] 0.675–0.996), Hb (OR 0.633, 95% CI 0.433–0.926), CK (OR 0.773 per 10 units, 95% CI 0.644–0.933), NSAID use (OR 0.099, 95% CI 0.020–0.494), diabetes mellitus (OR 6.024, 95% CI 1.508–24.390) and stage 4 Steinbrocker radiological grade (OR 10.309, 95% CI 2.994–35.714) were identified as independent relevant factors for Group A by a multifactorial analysis.Conclusion Renal function in RA patients with low BMI, diabetes, anemia and low CK may be overestimated using eGFR-Cr alone, and such patients need to be evaluated using eGFR-CysC.

MO538THE SHORT-TERM IMPACT OF HIGH DOSE INTRAVENOUS IRON USE ON RENAL FUNCTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND IRON DEFICIENCY WITHOUT ANAEMIA - A POST-HOC ANALYSIS OF A MULTICENTRE RANDOMIZED CONTROLLED TRIAL*

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Xenophon Kassianides ◽  
Adil Hazara ◽  
Philip A Kalra ◽  
Iain Macdougall ◽  
Sunil Bhandari
Keyword(s):  
Renal Function ◽  
Serum Creatinine ◽  
Cystatin C ◽  
Urinary Protein Excretion ◽  
Urinary Protein ◽  
High Dose ◽  
Third Generation ◽  
Protein Excretion ◽  
Iv Iron ◽  
The Impact

Abstract Background and Aims High dose intravenous (IV) iron is commonly used in patients with chronic kidney disease (CKD) but it remains unclear whether any short or long term impact on renal function exists. Studies using iron sucrose, a second generation IV iron compound suggest effects on proteinuria while evidence with third generation iron products revealed no impact on estimated glomerular filtration rate (eGFR). These newer iron compounds have compact iron-carbohydrate cores, potentially limiting the nephrotoxic effects of labile free iron. As a part of the Iron & Heart study, we examined the impact of high dose ferric derisomaltose (FDI), a third generation IV iron product, in patients with non-dialysis dependent CKD and iron deficiency on markers of renal injury and function using both established (serum creatinine, eGFR, 24-hour excretion of protein) and novel methods (Cystatin C, Neutrophil gelatinase-associated lipocalin (NGAL)). In addition, correlations between the different markers of renal dysfunction were examined alongside the impact of various confounders including age and diabetes mellitus on the reliability of such markers. Method This was a multicentre randomized double-blinded placebo-controlled study involving three tertiary renal centres in the United Kingdom. Patients with CKD stages 3b-5 (non-dialysis), a serum ferritin &lt;100 micrograms/L and/or transferrin saturation &lt;20% and a haemoglobin value of 110 – 150 g/L were enrolled. The participants were randomized 1:1 to receive either 1000 mg of FDI or placebo. Cystatin C, NGAL, serum creatinine eGFR and 24-hour urinary excretion of protein were measured at baseline and then repeated at 1- and 3- months. Changes in the levels of these were analysed both in terms of their absolute values and percentage change from baseline. Pearson’s coefficient (r) was calculated as a measure of correlation between changes in the follow-up values, and the level of statistical significance was set at less than 0.05. Results 54 patients were randomized; 26 to FDI and 28 to placebo. Patients in the two treatment arms were similar in age, gender, the prevalence of diabetes, baseline eGFR and urinary protein excretion (200mg vs 350mg/24hr in the FDI and placebo groups respectively, p = 0.2713). Compared to baseline levels, serum creatinine, cystatin C and NGAL did not change significantly in either arm (figure 1). There were no significant changes in urinary protein excretion both within and between groups (median change in urinary protein excretion: FDI: -10mg and -39mg/24hr; placebo: 0mg and 0mg/24hr at 1- and 3- months respectively, p&gt;0.05) There was a significant correlation between changes in cystatin C levels and serum creatinine (r = 0.6994, p&lt;0.0001) during follow-up. This correlation persisted when patients were stratified by an age of 65 years and presence of diabetes (figure 2). Changes in Cystatin C levels did not correlate well with changes in NGAL. Conclusion This post-hoc analysis of data from the Iron & Heart study indicates that high dose FDI did not cause any significant detriment in the short-term to renal function compared to placebo. This complements the safety profile of high dose third generation IV iron products and improves our understanding of their use in patients with CKD at their approved doses. There was a good correlation between cystatin C and creatinine, which was not affected by various sub-groups such as age or presence of diabetes mellitus. The analysis confirms the role of cystatin C as a robust biomarker of measuring renal function at least when compared to other established methods.

Sign in / Sign up

Export Citation Format

Share Document